Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine agonist presented as a 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h transdermal patch for transdermal use. It provides continuous dopaminergic stimulation over a 24‑hour period, improving symptom control and patient convenience. It is prescribed to manage motor symptoms in Parkinson's disease and to relieve uncomfortable sensations in Restless Legs Syndrome in adult patients.

GNH USA supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under a prescription‑only status.

Rotigotine is a non‑ergot dopamine agonist used in movement‑disorder therapy.

- Parkinson's disease: improves motor function and reduces “off” periods in adults with idiopathic Parkinson's disease. - Restless Legs Syndrome: lessens uncomfortable leg sensations and decreases the urge to move in adults with moderate to severe RLS.

Rotigotine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Application site reaction: erythema, itching or irritation at the patch site. - Dizziness: transient light‑headedness, especially on standing. - Somnolence: increased sleepiness or fatigue. - Dry mouth: reduced salivation leading to discomfort. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances, more common at higher doses. - Impulse control disorders: compulsive gambling, shopping or hypersexuality. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Orthostatic hypotension: marked blood pressure drop upon standing. - Depression or suicidal ideation: worsening mood or emergence of suicidal thoughts. - Severe allergic reaction: anaphylaxis or angioedema.

When prescribing Rotigotine, clinicians should consider several safety precautions to minimize risk.

- Monitor for hallucinations: visual or auditory hallucinations may appear, especially at higher doses. - Assess impulse control: patients may develop compulsive behaviors such as gambling or hypersexuality. - Check cardiovascular status: orthostatic hypotension and hypertension have been reported. - Evaluate psychiatric history: depression or suicidal thoughts may worsen. - Store at below 25°C: keep in the original pouch, protect from moisture and light.

Rotigotine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline, rasagiline): may cause hypertensive crisis. - Dopamine antagonists (e.g., typical antipsychotics): reduce therapeutic effect of rotigotine.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase rotigotine plasma levels. - Antihypertensive agents: additive blood‑pressure‑lowering effect. - SSRIs or SNRIs: may raise risk of impulse‑control disorders.